p 15

P15 is a collagen-mimetic peptide with the sequence GTPGPQGIAGQRGVV, which mimics the cell-binding domain of human type I collagen. P15 facilitates the adhesion, proliferation, and differentiation of osteoblasts. Biomaterials modified with P15 are applicable in research related to bone regeneration.

VPM-p15, a synthetic peptide agonist targeting the adhesion G protein-coupled receptor (GPCR) G2 (ADGRG2)—an orphan GPCR implicated in male infertility—facilitates cAMP accumulation in HEK293 cells expressing human ADGRG2, demonstrating efficacy with an EC50 value of 1.41 µM.

VPM-p15 is an optimized peptide agonist targeting the adhesion G protein-coupled receptor GPR64 (also known as ADGRG2 or HE6). It exhibits significantly higher affinity for GPR64 compared to the original p15 peptide. VPM-p15 significantly elevates cAMP levels, activating GPR64 and triggering downstream Gs, Gq, and G12/13 signaling pathways. This compound can be utilized in research focused on activation mechanisms of adhesion GPCR family members.

CIGB-300 acetate (P15-Tat acetate) is a peptide that acts as an inhibitor of casein kinase 2 (CK2). It exhibits anticancer properties by disrupting the phosphorylation activity of CK2. CIGB-300 acetate induces apoptosis in various tumor cell lines and is applicable for cancer research.

P505-15 Acetate is a selective inhibitor of spleen tyrosine kinase that acts by suppressing leukocyte immune function and inflammation and leading to a reduction in arthritis score and attenuated histological damage.

P-gp Inhibitor 15 (compound 7a), a nonsubstrate inhibitor of P-glycoprotein (Pgp), inhibits Pgp-ATPase activity and interferes with Pgp-mediated Rhodamine123 efflux. Additionally, this compound enhances the inhibitory effect of Paclitaxel on tumor progression in the KBV xenograft tumor model in nude mice [1].

SA-15-P inhibits the interactions of LAG-3/MHCII and LAG-3/FGL1 with respective IC50 values of 4.21 and 6.52 μM. The LAG-3/MHCII interaction is a target in immunotherapy.

CBP/p300-IN-15 (compound 13a) is a potent inhibitor of p300 (IC50: 2.5 nM) and CBP (IC50: 28.0 nM). It inhibits OVCAR-3 cells (EC50: 0.865 μM) and A2780 cells (EC50: 2.71 μM). CBP/p300-IN-15 can be used to study ovarian cancer.

5,10,15,20-Tetrakis(p-tolyl)porphyrin (TTP) is an organic compound classified within the porphyrin family, characterized by a cyclic structure formed from four pyrrole rings. TTP is a synthetic porphyrin commonly employed as a sensitizer in dye-sensitized solar cells and as a catalyst in various organic reactions. Owing to its unique structure, TTP exhibits a range of intriguing properties, including specific wavelength absorption and potential as a catalyst for different chemical reactions. In dye-sensitized solar cells, TTP aids in converting sunlight into electrical energy by absorbing photons and transferring electrons to the device's semiconductor layer. In organic chemistry, TTP is frequently utilized as a catalyst for reactions such as oxidation and reduction, selectively binding to certain substrates, making it a valuable tool for synthesizing complex molecules and studying their properties.

CP 154526 hydrochloride is a blood-brain barrier-penetrant, selective CRF1 (corticotropin-releasing factor receptor 1) antagonist (Ki = 2.7 nM) exhibiting thousands of times greater selectivity for CRF1 over CRF2, with anxiolytic and antidepressant activities.

CP 154,526 is a selective CRF1 receptor antagonist (Ki = 2.7 nM). CP 154,526 blocks CRF-induced activation of adenylate cyclase and the HPA axis.

Cgp 15425 is a bio-active chemical.

EP 157 is a bioactive chemical.

2,2,14,14-Tetramethyl-8-oxopentadecanedioic acid (compound example II-9) is a ketone used in the research of cardiovascular diseases, dysproteinemias, dyslipidemias, and glucose metabolism disorders.

CX-157 (KP 157) is a novel monoamine oxidase-A (MAO-A) inhibitor for the study of depression-like neurological disorders and cancer.

TMP-153 is a novel and potent ACAT inhibitor with an IC50 value of 5-10 nM for intestinal and hepatic ACAT in animals.TMP-153 has a hypocholesterolemic effect, inhibiting cholesterol uptake and lowering plasma cholesterol in rats and hamsters.

USP15-IN-1 is a potent USP15 inhibitor (IC50 is 3.76 μM) with high antiproliferative activity against non-small cell lung cancer and leukemia cells. As an interacting protein of cGAS, USP15 promotes cGAS to recognize DNA and activate downstream signaling pathways.

(S)-Enitociclib (VIP152) is a selective CDK9 inhibitor that induces complete regression of MYC+ lymphomas by inhibiting RNA polymerase II-mediated transcription of anti-apoptotic and pro-survival proteins.

LJP-1586 HCl, a highly selective inhibitor of vascular adhesion protein-1 (VAP-1), exhibits antiinflammation effect by reducing adhesion molecule expression and immune cell infiltration after intracerebral hemorrhage (ICH).

Bardoxolone Methyl (TP-155) is a synthetic triterpenoid that acts as an activator of the Nrf2 pathway and an inhibitor of the NF-κB pathway with potential anti-tumor and anti-inflammatory activities.

PARP10-IN-3 is a potent and selective mono-Adp-ribotransferase PARP10 inhibitor that inhibits human PARP10 (IC50:480 nM). PARP10-IN-3 also inhibited human PARP2 and human PARP15 with IC50 values of 1.7 μM.

PARP10-IN-2 is a potent inhibitor of PARP10, a mono-ADP-ribosyltransferase, with an IC50 value of 3.64 μM for human PARP10. It also inhibits PARP2 and PARP15, with IC50 values of 27 μM and 11 μM, respectively.

Samuraciclib hydrochloride (ICEC0942 hydrochloride) is a potent, selective, ATP competitive and oral active CDK7 inhibitor with IC50 of 41 nM. The selectivity of Samuraciclib hydrochloride is 45-, 15-, 230- and 30-fold higher than CDK1, CDK2 (IC50 is 578 nM), CDK5 and CDK9 respectively. Samuraciclib hydrochloride inhibits the growth of breast cancer cell lines with GI50 values between 0.2-0.3 μM. Samuraciclib hydrochloride has anti-tumor effects.

(±)-Enitociclib ((±)-BAY-1251152) is a racemic mixture of BAY-1251152, a highly selective inhibitor of PTEF/CDK9.